- Home
- RCKT
as 11-17-2025 3:45pm EST
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 340.9M | IPO Year: | N/A |
| Target Price: | $12.88 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.24 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.19 - $15.01 | Next Earning Date: | 11-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 3582.16% |
Latest Rocket Pharmaceuticals Inc. News
RCKT Breaking Stock News: Dive into RCKT Ticker-Specific Updates for Smart Investing
PR Newswire
5 days ago
Neurvati Neurosciences Appoints Carlos Martin as Chief Commercial Officer
GlobeNewswire
5 days ago
Leukocyte Adhesion Deficiency Market Analysis and Forecast, 2025-2035, Featuring Rocket Pharmaceuticals, Avalo Therapeutics, Orpha Labs, and AUG Therapeutics
Associated Press Finance
11 days ago
Rocket Pharmaceuticals: Q3 Earnings Snapshot
Business Wire
11 days ago
Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
Zacks
a month ago
RCKT Stock Up as FDA Accepts Resubmitted BLA for Gene Therapy
MT Newswires
a month ago
Rocket Pharma Gets FDA Review Date for Severe Immune Disorder Drug Candidate
Business Wire
a month ago
Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
Business Wire
a month ago
Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Compare RCKT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RCKT Rocket Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.